SCHEMBL6158035

SCHEMBL6158035

CCOC(=O)CCC(=O)c1ccccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 9/20 0.61
WNT3A P56704 7/20 0.61
ALDH1A1 P00352 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
TSHR P16473 1/20 0.53
ALDH3A1 P30838 1/20 0.53
LMNA P02545 2/20 0.52
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
MITF O75030 1/20 0.47
PKM P14618 1/20 0.47
RAB9A P51151 1/20 0.47
GRM4 Q14833 1/20 0.47
POLB P06746 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
NAPRT Q6XQN6 1/20 0.44
P4HTM Q9NXG6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11372856 0.98 CTNNB1 (0.60) CTNNB1WNT3AALDH1A1SMN1; SMN2TSHR
SCHEMBL24060895 0.91 CTNNB1 (0.58) CTNNB1WNT3AALDH1A1SMN1; SMN2TSHR
SCHEMBL601821 0.86 LMNA (0.54) CTNNB1WNT3AALDH1A1SMN1; SMN2TSHR
SCHEMBL2470002 0.83 CTNNB1 (0.71) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL10673145 0.82 CTNNB1 (0.52) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL17103798 0.80 CTNNB1 (0.51) CTNNB1WNT3AALDH1A1SMN1; SMN2TSHR
SCHEMBL29835204 0.80 CTNNB1 (0.56) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL23727696 0.80 CTNNB1 (0.56) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL30579595 0.80 CTNNB1 (0.63) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA
SCHEMBL745013 0.80 CTNNB1 (0.63) CTNNB1WNT3AALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117203194-A Novel compounds useful as STING agonists and uses thereof 北京加科思新药研发有限公司 2023-12-08 CN disclosed
US-10913734-B2 Substituted aminothiazoles BARUCH S. BLUMBERG INSTITUTE 2021-02-09 US disclosed
US-20190241552-A1 SUBSTITUTED AMINOTHIAZOLES BARUCH S. BLUMBERG INSTITUTE 2019-08-08 US disclosed
WO-2018013508-A1 SUBSTITUTED AMINOTHIAZOLES BARUCH S. BLUMBERG INSTITUTE (US) 2018-01-18 WO disclosed
US-6924300-B2 Oxyiminoalkanoic acid derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
EP-1077957-B1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-08-04 EP disclosed
EP-1428531-A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-06-16 EP disclosed
CN-1148361-C Oxyiminoalkanoic acid derivatives ����ҩƷ��ҵ��ʽ���� 2004-05-05 CN disclosed
US-20030186985-A1 Oxyiminoalkanoic acid derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
US-6495581-B1 DRUG FOR TREATING DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE, ARTERIAL SCLEROSIS AND IMPROVING INSULIN RESISTANCE, INFLAMMATORY DISEASE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-12-17 US disclosed
US-6251926-B1 OXYIMINOALKANOIC ACID DERIVATIVES HAVING HYPOGLYCEMIC EFFECT AND HYPOLIPIDEMIC EFFECT, IS USEFUL FOR TREATMENT OF DIABETES MELLITUS, HYPERLIPEMIA, IMPAIRED GLUCOSE TOLERANCE INFLAMMATORY DISEASE AND ARTERIOSCLEROSIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-06-26 US disclosed
CN-1300285-A Hydroxyiminoalkanoic Acid Derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2001-06-20 CN disclosed
EP-1077957-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Chemical Industries, Ltd. (JP) 2001-02-28 EP disclosed
WO-1999058510-A1 OXYIMINOALKANOIC ACID DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186985-A1 Oxyiminoalkanoic acid derivatives GPR119, IRS1, CPT1A CTNNB1 3588/4885WNT3A 4123/4885ALDH1A1 2409/4885
US-10913734-B2 Substituted aminothiazoles ABAT, AADAT, BCAT1 CTNNB1 2719/4885WNT3A 4631/4885ALDH1A1 571/4885
US-20190241552-A1 SUBSTITUTED AMINOTHIAZOLES ABAT, AADAT, BCAT1 CTNNB1 2719/4885WNT3A 4631/4885ALDH1A1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.